The Potential of CAR T Cell Therapy in Pancreatic Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Oct 16

PMID 30319627

Citations 75

Authors

Mehmet Akce

Mohammad Y Zaidi

Edmund K Waller

Bassel F El-Rayes

Gregory B Lesinski

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer has a dismal prognosis and effective treatment options are limited. It is projected to be the second most common cause of cancer related mortality in the United States by 2030 and there is urgent unmet need for novel systemic treatment options. Immunotherapy with antibodies targeting PD-1, PD-L1, CTLA-4 has not shown clinical activity in unselected pancreatic cancer, emphasizing the need for combination immunotherapy approaches or other therapeutic strategies. As such, chimeric antigen receptor (CAR) T cell therapy represents an emerging therapeutic option for pancreatic cancer. This modality utilizes genetically engineered T cells that are redirected to specific cancer-associated antigens to elicit potent cytotoxic activity. This review summarizes the available preclinical data and highlights early phase clinical trials using CAR T cell approaches in pancreatic cancer, a disease state that is gaining attention as a conduit for cell therapy. Future directions in application of CAR T cell therapy are also considered including its ability to be directed against novel epitopes and combined with other therapeutic regimens.

Citing Articles

A stumbling block in pancreatic cancer treatment: drug resistance signaling networks.

Liu J, Zhang B, Huang B, Zhang K, Guo F, Wang Z Front Cell Dev Biol. 2025; 12:1462808.

PMID: 39872846 PMC: 11770040. DOI: 10.3389/fcell.2024.1462808.

The value of a metabolic and immune-related gene signature and adjuvant therapeutic response in pancreatic cancer.

Ni D, Wu J, Pan J, Liang Y, Xu Z, Yan Z Front Genet. 2025; 15:1475378.

PMID: 39867576 PMC: 11758928. DOI: 10.3389/fgene.2024.1475378.

Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches.

Ramalingam P, Premkumar T, Sundararajan V, Hussain M, Arumugam S Discov Oncol. 2024; 15(1):592.

PMID: 39453574 PMC: 11511808. DOI: 10.1007/s12672-024-01455-6.

Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.

Fu Y, Guo X, Sun L, Cui T, Wu C, Wang J Elife. 2024; 13.

PMID: 39146202 PMC: 11326777. DOI: 10.7554/eLife.95009.

Expression of CD45 in non-hematopoietic cells: implications in regenerative medicine and disease management.

Das M, Teli P, Vaidya A, Kale V Regen Med. 2024; 19(7-8):407-419.

PMID: 39058408 PMC: 11370962. DOI: 10.1080/17460751.2024.2378627.

References

Kochenderfer J, Wilson W, Janik J, Dudley M, Stetler-Stevenson M, Feldman S . Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116(20):4099-102. PMC: 2993617. DOI: 10.1182/blood-2010-04-281931. View

Boon T, Cerottini J, Van den Eynde B, van der Bruggen P, Van Pel A . Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994; 12:337-65. DOI: 10.1146/annurev.iy.12.040194.002005. View

Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf I, Hombach A . T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology. 2012; 143(4):1095-107.e2. DOI: 10.1053/j.gastro.2012.06.037. View

Torikai H, Cooper L . Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors. Mol Ther. 2016; 24(7):1178-86. PMC: 5088751. DOI: 10.1038/mt.2016.106. View

Kochenderfer J, Somerville R, Lu T, Shi V, Bot A, Rossi J . Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol. 2017; 35(16):1803-1813. PMC: 5455597. DOI: 10.1200/JCO.2016.71.3024. View

Fraietta J, Lacey S, Orlando E, Pruteanu-Malinici I, Gohil M, Lundh S . Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018; 24(5):563-571. PMC: 6117613. DOI: 10.1038/s41591-018-0010-1. View

Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M . HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci. 2009; 100(7):1243-7. PMC: 11159349. DOI: 10.1111/j.1349-7006.2009.01176.x. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Bailey S, Nelson M, Majchrzak K, Bowers J, Wyatt M, Smith A . Human CD26 T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nat Commun. 2017; 8(1):1961. PMC: 5719008. DOI: 10.1038/s41467-017-01867-9. View

10.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B . A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254(5038):1643-7. DOI: 10.1126/science.1840703. View

11.

Carpenito C, Milone M, Hassan R, Simonet J, Lakhal M, Suhoski M . Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009; 106(9):3360-5. PMC: 2651342. DOI: 10.1073/pnas.0813101106. View

12.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

13.

Beatty G, Haas A, Maus M, Torigian D, Soulen M, Plesa G . Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014; 2(2):112-20. PMC: 3932715. DOI: 10.1158/2326-6066.CIR-13-0170. View

14.

Smith T, Moffett H, Stephan S, Opel C, Dumigan A, Jiang X . Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest. 2017; 127(6):2176-2191. PMC: 5451231. DOI: 10.1172/JCI87624. View

15.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

16.

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

17.

Popovic A, Jaffee E, Zaidi N . Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest. 2018; 128(8):3209-3218. PMC: 6063475. DOI: 10.1172/JCI120775. View

18.

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

19.

Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-51. PMC: 2862534. DOI: 10.1038/mt.2010.24. View

20.

Jacob J, Bellach J, Grutzmann R, Alldinger I, Pilarsky C, Dietel M . Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology. 2004; 4(5):454-60. DOI: 10.1159/000079824. View